Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Fara Brasó-Maristany"'
Autor:
Anwesha Chaudhury, Nuria Chic, Tetiana Taran, D. Martinez, Nadia Solovieff, Karen Rodriguez-Lorenc, Fara Brasó-Maristany, Aleix Prat, Faye Su, Laia Paré, Olga Martínez, Naveen Babbar
Publikováno v:
Cancer Research. 81:GS1-04
Background: The prognostic and predictive value of the 4 main intrinsic subtypes of breast cancer (ie, luminal A [LumA], luminal B [LumB], human epidermal growth factor receptor 2 enriched [HER2E], and basal-like) in hormone receptor-positive, HER2
Autor:
Federico Rojo, Kevin R. Mott, Jeffery M. Rosen, Juan Miguel Cejalvo, Octavio Burgues, Susana García-Recio, Lisa A. Carey, Aleix Prat, Eduardo Martínez de Dueñas, Fara Brasó-Maristany, Alisha R. Coffey, Joel S. Parker, Ana Lluch, Xiaping He, Sara R. Selitsky, Charles M. Perou, Cheng Fan, Daniel P. Hollern, Joseph P. Garay, Michael P. East, Aatish Thennavan, Patricia Galván, David Marron, Joan Albanell, Gary L. Johnson
Publikováno v:
J Clin Invest
JOURNAL OF CLINICAL INVESTIGATION
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
JOURNAL OF CLINICAL INVESTIGATION
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
Mechanisms driving tumor progression from less aggressive subtypes to more aggressive states represent key targets for therapy. We identified a subset of luminal A primary breast tumors that give rise to HER2-enriched (HER2E) subtype metastases, but
Autor:
Tetiana Taran, Nadia Solovieff, Olga Martínez-Sáez, D. Martinez, Naveen Babbar, Agnes Lteif, Fara Brasó-Maristany, Anwesha Chaudhury, Nuria Chic, Aleix Prat, Laia Paré, Fei Su
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(13)
PURPOSE The prognostic and predictive value of intrinsic subtypes in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer treated with endocrine therapy and ribociclib (RIB) is currently unknown. We
Autor:
Miguel Martín, Laia Paré, Barbara Adamo, Roberta Fasani, Blanca Gonzalez-Farre, Benedetta Conte, Giovanna Sabarese, Carlos H. Barrios, Fara Brasó-Maristany, Esther Sanfeliu, Mariavittoria Locci, Giuseppe Perrone, Francesca Zalfa, Esther Barnadas, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, Ana Lluch, Maria Vidal, Joaquín Gavilá, Tomás Pascual, Aleix Prat, Francesco Schettini, Sabino De Placido, Patricia Villagrasa, Vicente Peg, Nuria Chic, Juan Miguel Cejalvo
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Scientia
NPJ Breast Cancer
npj Breast Cancer, Vol 7, Iss 1, Pp 1-13 (2021)
Universidad de Barcelona
Scientia
NPJ Breast Cancer
npj Breast Cancer, Vol 7, Iss 1, Pp 1-13 (2021)
Càncer de mama; Genòmica del càncer; Recerca translacional Cáncer de mama; Genómica del cáncer; Investigación traslacional Breast cancer; Cancer genomics; Translational research Novel antibody-drug conjugates against HER2 are showing high acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c10b99479fa39b069aa421ecf890520
http://hdl.handle.net/2445/175264
http://hdl.handle.net/2445/175264
Autor:
Aranzazu Fernandez-Martinez, Barbara Adamo, Blanca Gonzalez-Farre, Lisa A. Carey, Francesco Schettini, Benedetta Conte, Charles M. Perou, Jamunarani Veeraraghavan, Jan C. Brase, Sabino De Placido, Tomás Pascual, Mariavittoria Locci, Pierfranco Conte, Patricia Villagrasa, Montserrat Muñoz, Sonia Pernas, Fara Brasó-Maristany, Olga Martínez, Patricia Galván, Maria Vidal, Mothaffar F. Rimawi, C. Kent Osborne, Carla Rognoni, Gaia Griguolo, Rachel Schiff, Nuria Chic, Valentina Guarneri, Aleix Prat
Publikováno v:
Cancer Treat Rev
Background: HER2-positive (HER2+) breast cancer (BC) comprises all the four PAM50 molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be associated with higher pathological complete response (pCR) rates following anti-HER2-based reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::456360a8625da925d93580bf31f87b0f
https://europepmc.org/articles/PMC7230134/
https://europepmc.org/articles/PMC7230134/
Autor:
Ronald E. Kates, Laura Barberá, Miriam Cuatrecasas, Nadia Harbeck, Oleg Gluz, Fara Brasó-Maristany, Patricia Villagrasa, Tommaso Giarratano, Dolors Soy, Maria Vidal, Tomás Pascual, David Pesantez, Vassilena Tsvetkova, Patricia Galván, Aleix Prat, Hans Kreipe, Laia Paré, Mathias Christgen, Montserrat Muñoz, Barbara Adamo, Inés Monge-Escartín, Blanca Gonzalez-Farre, Maria Vittoria Dieci, D. Martinez, Pierfranco Conte, Tamara Saurí, Valentina Guarneri, Nuria Chic, Gaia Griguolo
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Cancers, Vol 12, Iss 1902, p 1902 (2020)
Cancers
Volume 12
Issue 7
Universidad de Barcelona
Cancers, Vol 12, Iss 1902, p 1902 (2020)
Cancers
Volume 12
Issue 7
Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy
however, not all patients benefit. H
however, not all patients benefit. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30b95522a064c1502a80af4150f0652a
http://hdl.handle.net/2445/174260
http://hdl.handle.net/2445/174260
Autor:
Noelia Martínez, Paolo Nuciforo, Begoña Bermejo, Laia Paré, Patricia Villagrasa, Serafin Morales, J. Alarcón, Eva Ciruelos, Olga Martínez, Tomás Pascual, Aleix Prat, Montserrat Muñoz, Barbara Adamo, I Garau, Sara Gregorio, Fara Brasó-Maristany, Gaia Griguolo, Javier Cortes, Roger R. Gomis, Nuria Chic, Rafael López, Sonia Pernas, Maria Vidal, Antonio Llombart-Cussac, Mafalda Oliveira, Patricia Galván, Eduardo Martínez, Luis Manso
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Scientia
Nature Communications
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
NATURE COMMUNICATIONS
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Nature Communications, Vol 11, Iss 1, Pp 1-11 (2020)
Universidad de Barcelona
Scientia
Nature Communications
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
NATURE COMMUNICATIONS
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Nature Communications, Vol 11, Iss 1, Pp 1-11 (2020)
The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highly addicted to the HER2 pathway. However, similar to 20-60% of HER2+/HER2-E tumors do not achieve a complete response following anti-HER2 therapies. Here we evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c3ed99d6d73c9674b22dd22eda471f4
http://hdl.handle.net/2445/173290
http://hdl.handle.net/2445/173290
Autor:
Fara Brasó-Maristany, Mònica Sánchez-Guixé, Andreu Ódena, Aleix Prat, Olga Rodriguez, Yasir H. Ibrahim, Alejandra Bruna, Elza C. de Bruin, Barry R. Davies, Alan Barnicle, Laia Monserrat, Judit Grueso, Carlos Caldas, Guillermo Villacampa, Nicholas C. Turner, Avinash Reddy, Paolo Nuciforo, Albert Gris-Oliver, Joaquín Arribas, Violeta Serra, Gordon B. Mills, Maurizio Scaltriti, Caroline S. Hirst, Mafalda Oliveira, Gaia Schiavon, Cristina Saura, Marta Guzman, Marta Palafox, Pedram Razavi, Mireia Parés, Rodrigo Dienstmann
Publikováno v:
Clin Cancer Res
Purpose: AZD5363/capivasertib is a pan-AKT catalytic inhibitor with promising activity in combination with paclitaxel in triple-negative metastatic breast cancer harboring PI3K/AKT-pathway alterations and in estrogen receptor–positive breast cancer
Autor:
Montserrat Muñoz, Tomás Pascual, Charles M. Perou, Aranzazu Fernandez-Martinez, Aleix Prat, Juan Miguel Cejalvo, Roger R. Gomis, Fara Brasó-Maristany
Publikováno v:
Cancer Treatment Reviews. 67:63-70
Gene expression profiling has had a considerable impact on our understanding of breast cancer biology. During the last decade, 4 intrinsic molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched [HER2-E] and Basal-like) have been ide
Autor:
Olga Martínez-Sáez, Francesco Schettini, Nuria Chic, D. Martinez, Joaquín Gavilá, Cristina Saura, Charles M. Perou, Patricia Galván, Meritxell Bellet, Eva Ciruelos, Barbara Adamo, Blanca Gonzalez-Farre, Lisa A. Carey, Javier Cortes, T. Pascual, Aleix Prat, Mafalda Oliveira, Jesus Soberino, Sonia Pernas, Maria Vidal, Montserrat Muñoz, Esther Sanfeliu, Fara Brasó-Maristany
Publikováno v:
EBioMedicine, Vol 69, Iss, Pp 103451-(2021)
EBioMedicine
EBioMedicine
Background Chemotherapy efficacy in early-stage hormone receptor-positive (HR+) breast cancer (BC) according to menopausal status needs a biological explanation. Methods We compared early-stage HR+ BC biological features before and after (neo)adjuvan